MCID: CRB004
MIFTS: 45

Cerebral Artery Occlusion malady

Categories: Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Cerebral Artery Occlusion

Aliases & Descriptions for Cerebral Artery Occlusion:

Name: Cerebral Artery Occlusion 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:10127
ICD9CM 35 434 434.9
UMLS 69 C0028790

Summaries for Cerebral Artery Occlusion

MalaCards based summary : Cerebral Artery Occlusion is related to cerebritis and ischemia. An important gene associated with Cerebral Artery Occlusion is BDNF (Brain Derived Neurotrophic Factor), and among its related pathways/superpathways are PEDF Induced Signaling and Spinal Cord Injury. The drugs Ethanol and Heparin have been mentioned in the context of this disorder. Affiliated tissues include brain, endothelial and cortex, and related phenotypes are cellular and growth/size/body region

Related Diseases for Cerebral Artery Occlusion

Diseases related to Cerebral Artery Occlusion via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 60)
id Related Disease Score Top Affiliating Genes
1 cerebritis 11.0
2 ischemia 10.4
3 neuronitis 10.3
4 renal fibrosis 10.2 BDNF GDNF
5 brain edema 10.1
6 brain injury 10.1
7 7q11.23 duplication syndrome 10.1 NOS1 NOS3
8 renovascular hypertension 10.0 NOS1 NOS3
9 corneal ulcer 10.0 BDNF GDNF
10 aphasia 10.0 NOS1 NOS3
11 vestibulocochlear nerve disease 10.0 GDNF NOS1
12 schwannoma of twelfth cranial nerve 10.0 ADAMTS1 GDNF
13 hypoxia 10.0
14 splenic marginal zone lymphoma 10.0 BDNF GDNF NOS1
15 endotheliitis 10.0
16 wegmann jones smith syndrome 9.9 CNTF ODC1
17 aneurysm 9.9
18 brain ischemia 9.9
19 gastroduodenal crohn's disease 9.9 GDNF NOS1 NOS3
20 cowpox 9.9 IL1RN ODC1
21 carotid artery dissection 9.9
22 mutism 9.9
23 akinetic mutism 9.9
24 epithelioid type angiomyolipoma 9.8 BDNF CNTF GDNF
25 cervicitis 9.7
26 cerebral hypoxia 9.7
27 hyperglycemia 9.7
28 endocarditis 9.7
29 hemiplegia 9.7
30 choroiditis 9.7
31 moyamoya disease 9.7
32 spondyloarthropathy 1 9.7 BDNF GDNF NOS1 NOS3
33 long qt syndrome 5 9.7 BDNF CNTF GDNF NOS1
34 acute myocardial infarction 9.6
35 dementia 9.6
36 arteriovenous fistula 9.6
37 epilepsy 9.6
38 hypereosinophilic syndrome 9.6
39 acromegaly 9.6
40 neonatal stroke 9.6
41 neutropenia 9.6
42 osteopetrosis 9.6
43 retinitis 9.6
44 ischemic retinopathy 9.6
45 thrombocytopenia 9.6
46 artery disease 9.6
47 infective endocarditis 9.6
48 myocardial infarction 9.6
49 thrombosis 9.6
50 coronary artery disease 9.6

Graphical network of the top 20 diseases related to Cerebral Artery Occlusion:



Diseases related to Cerebral Artery Occlusion

Symptoms & Phenotypes for Cerebral Artery Occlusion

MGI Mouse Phenotypes related to Cerebral Artery Occlusion:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.8 BDNF CNTF GDNF IL1RN NOS1 NOS3
2 growth/size/body region MP:0005378 9.7 NOS1 NOS3 ODC1 ADAMTS1 BDNF GDNF
3 reproductive system MP:0005389 9.1 ADAMTS1 BDNF GDNF IL1RN NOS1 NOS3
4 obsolete other MP:0005395 8.96 NOS1 NOS3

Drugs & Therapeutics for Cerebral Artery Occlusion

Drugs for Cerebral Artery Occlusion (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 442)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3 9005-49-6 772 46507594
3
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
4
Ticlopidine Approved Phase 4,Phase 3,Phase 2 55142-85-3 5472
5
Tirofiban Approved Phase 4 144494-65-5 60947
6
Citalopram Approved Phase 4,Phase 3 59729-33-8 2771
7 Nadroparin Approved Phase 4 9041-08-1
8
Dalteparin Approved Phase 4 9041-08-1
9
Probucol Approved Phase 4 23288-49-5 4912
10
Pravastatin Approved Phase 4 81093-37-0 54687
11
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
12
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
13
Paclitaxel Approved, Vet_approved Phase 4,Phase 2,Phase 3 33069-62-4 36314
14
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
15
Dipyridamole Approved Phase 4,Phase 2 58-32-2 3108
16
Acetaminophen Approved Phase 4,Phase 3,Phase 2 103-90-2 1983
17
Metformin Approved Phase 4,Phase 2 657-24-9 14219 4091
18
Amlodipine Approved Phase 4,Phase 3 88150-42-9 2162
19
Donepezil Approved Phase 4,Phase 3,Phase 1 120014-06-4 3152
20
Galantamine Approved Phase 4,Phase 3,Phase 2 357-70-0 9651 908828, 9651
21 Piracetam Approved Phase 4 7491-74-9
22
Cilostazol Approved Phase 4 73963-72-1 2754
23
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3 76631-46-4, 113775-47-6 68602 5311068 56032
24
Dobutamine Approved Phase 4 34368-04-2 36811
25
Sevoflurane Approved, Vet_approved Phase 4,Phase 2 28523-86-6 5206
26
Abciximab Approved Phase 4,Phase 3,Phase 2,Phase 1 143653-53-6
27
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 1 137-58-6 3676
28
Remifentanil Approved Phase 4,Phase 3 132875-61-7 60815
29
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 1 2180-92-9, 38396-39-3 2474
30
Everolimus Approved Phase 4,Phase 3 159351-69-6 6442177
31
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 2078-54-8 4943
32
Hydrocodone Approved, Illicit Phase 4 125-29-1 5284569
33
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
34
Bivalirudin Approved, Investigational Phase 4,Phase 2,Phase 3 128270-60-0 16129704
35
Benzocaine Approved Phase 4,Phase 3 1994-09-7, 94-09-7 2337
36
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
37
Nicergoline Approved Phase 4 27848-84-6 34040
38
Sirolimus Approved, Investigational Phase 4,Phase 3 53123-88-9 5284616 6436030 46835353
39
Prilocaine Approved Phase 4 721-50-6 4906
40
Guaifenesin Approved, Vet_approved Phase 4 93-14-1 3516
41
Coal tar Approved Phase 4 8007-45-2
42
Warfarin Approved Phase 4,Phase 3 81-81-2 6691 54678486
43
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
44
Rivaroxaban Approved Phase 4,Phase 3 366789-02-8
45
Glyburide Approved Phase 4 10238-21-8 3488
46
Losartan Approved Phase 4 114798-26-4 3961
47
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
48
Ranibizumab Approved Phase 4 347396-82-1 459903
49
Desflurane Approved Phase 4 57041-67-5 42113
50
Clopidogrel Approved, Nutraceutical Phase 4,Phase 3,Phase 2 120202-66-6, 113665-84-2 60606

Interventional clinical trials:

(show top 50) (show all 782)
id Name Status NCT ID Phase
1 A Randomized Double Blind Placebo Control Study of Huang-Chi-Wu-Wu- Tang in Patients With Intracranial Arterial Stenosis Unknown status NCT01553643 Phase 4
2 Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD Unknown status NCT01531829 Phase 4
3 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
4 Treatment of Cranial Internal Carotid Artery Aneurysm With Willis Covered Stent and Coil Embolization Unknown status NCT01029938 Phase 4
5 Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4
6 Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting Unknown status NCT01572623 Phase 4
7 Effect of BNP (Brain Natriuretic Peptides) on Endothelial Dysfunction Induced by Coronary Angioplasty Unknown status NCT00262574 Phase 4
8 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
9 Comparing Carotid Stenting With Endarterectomy in Severe Asymptomatic Carotid Stenosis Unknown status NCT00772278 Phase 4
10 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4
11 Incidence of Acute Cerebrovascular Events Using Either Minimized or Standard Cardiopulmonary Bypass Circuit Unknown status NCT00862160 Phase 4
12 HYdrogel Coil Versus Bare Platinum Coil in Recanalization Imaging Data Study Unknown status NCT01516658 Phase 4
13 Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4
14 Atorvastatin in Acute Stroke Treatment Completed NCT02225834 Phase 4
15 Cerebral Embolic Load in Patients Undergoing Surgical Aortic Valve Replacement: A Comparison of the Conventional With the Minimized Extracorporeal Circulation Technique Using Transcranial Doppler Ultrasound Completed NCT02308566 Phase 4
16 Influence of the Concentration of the Local Anesthetic Ropivacaine on the Quality of a Ultrasound Guided Intermediate Cervical Block. Completed NCT01759940 Phase 4
17 Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II Completed NCT00130039 Phase 4
18 Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients Completed NCT01325935 Phase 4
19 Researching AXIUM Coiling Experience and Recanalization (RACER) Completed NCT00703794 Phase 4
20 Platelet Inhibition and Transcranial Doppler (TCD)-Detected Microemboli During and After Carotid Artery Stenting (CAS) in Asymptomatic Patients Prior to Cardiac Surgery Completed NCT01146301 Phase 4
21 Nobori Dual Antiplatelet Therapy as Appropriate Duration Completed NCT01514227 Phase 4
22 A Single Center of Carotid Stenting With Distal Protection for the Treatment of Obstructive Carotid Artery Disease Completed NCT00178672 Phase 4
23 A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease Completed NCT00162370 Phase 4
24 Emboshield® and Xact® Post Approval Carotid Stent Trial (The EXACT Study) Completed NCT00287508 Phase 4
25 ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial Completed NCT00161070 Phase 4
26 The Dual Antiplatelet Therapy Study (DAPT Study) Completed NCT00977938 Phase 4
27 The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study) Completed NCT01188824 Phase 4
28 Platelet Hyperreactivity to Aspirin and Stroke Completed NCT00766896 Phase 4
29 The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study) Completed NCT00250380 Phase 4
30 Effect on Cerebral Oxygenation by Sevoflurane or Propofol Using Near-infrared Spectroscopy in Carotid Endarterectomy Completed NCT02609087 Phase 4
31 Effect of IV Acetaminophen on Patients in the Neurocritical Care Unit Completed NCT01948505 Phase 4
32 Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject Completed NCT00823875 Phase 4
33 Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel Completed NCT00405717 Phase 4
34 Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention Completed NCT00404781 Phase 4
35 Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Completed NCT00262561 Phase 4
36 The Effect of Atorvastatin and Pioglitazone on Carotid Atherosclerosis With the Use of Positron Emission Tomography-computed Tomography (PET-CT) Completed NCT01341730 Phase 4
37 MAPS Trial: Matrix And Platinum Science Completed NCT00396981 Phase 4
38 Effect of 5 Years of GH Replacement on Atherosclerosis Completed NCT00462475 Phase 4
39 Stop Atherosclerosis in Native Diabetics Study Completed NCT00147251 Phase 4
40 Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Completed NCT00110448 Phase 4
41 Carotid Atherosclerosis: MEtformin for Insulin ResistAnce Study Completed NCT00723307 Phase 4
42 Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Carotid Intima-media Thickness (CIMT) Completed NCT01203982 Phase 4
43 Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions Completed NCT00847860 Phase 4
44 The Registry to Study Safety and Performance of the CORDIS Vascular Reconstruction Device and Delivery System Completed NCT00486226 Phase 4
45 Carotid Atherosclerosis Regression at Magnetic Resonance Assessment. Completed NCT00307307 Phase 4
46 TRAIL: Treatment of Intracranial Aneurysms With LVIS® System Completed NCT02921711 Phase 4
47 A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels Completed NCT00327691 Phase 4
48 Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST) Completed NCT00442845 Phase 4
49 Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets Completed NCT00442325 Phase 4
50 Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine Completed NCT01009476 Phase 4

Search NIH Clinical Center for Cerebral Artery Occlusion

Genetic Tests for Cerebral Artery Occlusion

Anatomical Context for Cerebral Artery Occlusion

MalaCards organs/tissues related to Cerebral Artery Occlusion:

39
Brain, Endothelial, Cortex, Bone, Bone Marrow, Retina, Thalamus

Publications for Cerebral Artery Occlusion

Articles related to Cerebral Artery Occlusion:

(show top 50) (show all 644)
id Title Authors Year
1
Acute Cerebral Artery Occlusion by a Calcified Embolus with False Patency Sign on Computed Tomographic Angiography. ( 27789151 )
2017
2
Intravenous infusion of mesenchymal stem cells inhibits intracranial hemorrhage after recombinant tissue plasminogen activator therapy for transient middle cerebral artery occlusion in rats. ( 28059661 )
2017
3
Neuroprotective effect of lercanidipine in middle cerebral artery occlusion model of stroke in rats. ( 27794423 )
2017
4
Lack of functional P2X7 receptor aggravates brain edema development after middle cerebral artery occlusion. ( 27048203 )
2016
5
Hemodynamic changes in a rat parietal cortex after endothelin-1-induced middle cerebral artery occlusion monitored by optical coherence tomography. ( 27469083 )
2016
6
Clinical Outcome Predicted by Collaterals Depends on Technical Success of Mechanical Thrombectomy in Middle Cerebral Artery Occlusion. ( 27856113 )
2016
7
In Vitro Differentiation of Bone Marrow Mesenchymal Stem Cells into Neuron-Like Cells by Cerebrospinal Fluid Improves Motor Function of Middle Cerebral Artery Occlusion Rats. ( 27833584 )
2016
8
Multiple cerebral artery occlusion due to non-bacterial thrombotic endocarditis: an autopsy case report. ( 26960272 )
2016
9
Tongxinluo reduces brain edema and inhibits post-ischemic inflammation after middle cerebral artery occlusion in rats. ( 26805468 )
2016
10
Transarterial regional hypothermia provides robust neuroprotection in a rat model of permanent middle cerebral artery occlusion with transient collateral hypoperfusion. ( 27663968 )
2016
11
A modification of intraluminal middle cerebral artery occlusion/reperfusion model for ischemic stroke with laser Doppler flowmetry guidance in mice. ( 27843320 )
2016
12
Knockout of Programmed Cell Death 5 (PDCD5) gene attenuates neuron injury after middle cerebral artery occlusion in mice. ( 27608954 )
2016
13
Vessel Dilation Attenuates Endothelial Dysfunction Following Middle Cerebral Artery Occlusion in Hyperglycemic Rats. ( 26842484 )
2016
14
The Carotid and Middle cerebral artery Occlusion Surgery Study (CMOSS): a study protocol for a randomised controlled trial. ( 27852286 )
2016
15
Middle Cerebral Artery Occlusion Model of Stroke in Rodents: A Step-by-Step Approach. ( 26958146 )
2016
16
Acute Hyperglycemia Does Not Affect Brain Swelling or Infarction Volume After Middle Cerebral Artery Occlusion in Rats. ( 26463957 )
2016
17
The Efficacy of Hyperbaric Oxygen Therapy on Middle Cerebral Artery Occlusion in Animal Studies: A Meta-Analysis. ( 26859390 )
2016
18
Optical inhibition of striatal neurons promotes focal neurogenesis and neurobehavioral recovery in mice after middle cerebral artery occlusion. ( 27055780 )
2016
19
Cerebral Hemodynamics and Vascular Reactivity in Mild and Severe Ischemic Rodent Middle Cerebral Artery Occlusion Stroke Models. ( 27358581 )
2016
20
Time to redefine success? TICI 3 versus TICI 2b recanalization in middle cerebral artery occlusion treated with thrombectomy. ( 26888952 )
2016
21
Cerebral Arterial Occlusion Did Not Promote the Prevalence of Cerebral Amyloid Angiopathy. ( 27497483 )
2016
22
Surgical Approach for Middle Cerebral Artery Occlusion and Reperfusion Induced Stroke in Mice. ( 27805602 )
2016
23
ChAT-positive neurons participate in subventricular zone neurogenesis after middle cerebral artery occlusion in mice. ( 27609645 )
2016
24
Transneuronal Degeneration of Thalamic Nuclei following Middle Cerebral Artery Occlusion in Rats. ( 27597962 )
2016
25
Perfusion-Weighted MRI Parameters for Prediction of Early Progressive Infarction in Middle Cerebral Artery Occlusion. ( 27446514 )
2016
26
Pretreatment of 6-shogaol attenuates oxidative stress and inflammation in middle cerebral artery occlusion-induced mice. ( 27346834 )
2016
27
Assessment of Blood-Brain Barrier Permeability by Dynamic Contrast-Enhanced MRI in Transient Middle Cerebral Artery Occlusion Model after Localized Brain Cooling in Rats. ( 27587960 )
2016
28
Multi-modal assessment of neurovascular coupling during cerebral ischaemia and reperfusion using remote middle cerebral artery occlusion. ( 27629101 )
2016
29
Electroacupuncture Attenuates Cerebral Ischemia and Reperfusion Injury in Middle Cerebral Artery Occlusion of Rat via Modulation of Apoptosis, Inflammation, Oxidative Stress, and Excitotoxicity. ( 27123035 )
2016
30
Neuroprotective effects of Chrysophanol against inflammation in middle cerebral artery occlusion mice. ( 27450437 )
2016
31
Comparisons between Garcia, Modo, and Longa rodent stroke scales: Optimizing resource allocation in rat models of focal middle cerebral artery occlusion. ( 27084232 )
2016
32
Progesterone treatment shows greater protection in brain vs. retina in a rat modelA of middle cerebral artery occlusion: Progesterone receptor levels may play an important role. ( 27802245 )
2016
33
Erratum to: Lack of functional P2X7 receptor aggravates brain edema development after middle cerebral artery occlusion. ( 27826687 )
2016
34
Fluid-Attenuated Inversion Recovery Vascular Hyperintensity Topography, Novel Imaging Marker for Revascularization in Middle Cerebral Artery Occlusion. ( 27659851 )
2016
35
rLj-RGD3, a Novel Recombinant Toxin Protein from Lampetra japonica, Protects against Cerebral Reperfusion Injury Following Middle Cerebral Artery Occlusion Involving the Integrin-PI3K/Akt Pathway in Rats. ( 27768719 )
2016
36
Macrophage depletion reduced brain injury following middle cerebral artery occlusion in mice. ( 26873581 )
2016
37
Is shorter transient middle cerebral artery occlusion (t-MCAO) duration better in stroke experiments on diabetic female Sprague Dawely rats? ( 27541599 )
2016
38
Galectin-3 causes enteric neuronal loss in mice after left sided permanent middle cerebral artery occlusion, a model of stroke. ( 27612206 )
2016
39
The temporal evolution of diffusional kurtosis imaging in an experimental middle cerebral artery occlusion (MCAO) model. ( 27125873 )
2016
40
A New Approach of Short Wave Protection against Middle Cerebral Artery Occlusion/Reperfusion Injury via Attenuation of Golgi Apparatus Stress by Inhibition of Downregulation of Secretory Pathway Ca(2+)-ATPase Isoform 1 in Rats. ( 27133772 )
2016
41
Lenticulostriate infarctions after successful mechanical thrombectomy in middle cerebral artery occlusion. ( 26940316 )
2016
42
Integrated Analysis of Expression Profile Based on Differentially Expressed Genes in Middle Cerebral Artery Occlusion Animal Models. ( 27213359 )
2016
43
Sex differences in astrocyte and microglia responses immediately following middle cerebral artery occlusion in adult mice. ( 27717807 )
2016
44
Acute Hyperglycemia Is Associated with Immediate Brain Swelling and Hemorrhagic Transformation After Middle Cerebral Artery Occlusion in Rats. ( 26463955 )
2016
45
Determinants of leptomeningeal collateral flow in stroke patients with a middle cerebral artery occlusion. ( 27438804 )
2016
46
Long-term survival in permanent middle cerebral artery occlusion: a model of malignant stroke in rats. ( 27329690 )
2016
47
A Comparative Study of Variables Influencing Ischemic Injury in the Longa and Koizumi Methods of Intraluminal Filament Middle Cerebral Artery Occlusion in Mice. ( 26870954 )
2016
48
Ischemic brain injury decreases dynamin-like protein 1 expression in a middle cerebral artery occlusion animal model and glutamate-exposed HT22 cells. ( 28053612 )
2016
49
Pharmacokinetic Comparison of Scutellarin and Paeoniflorin in Sham-Operated and Middle Cerebral Artery Occlusion Ischemia and Reperfusion Injury Rats after Intravenous Administration of Xin-Shao Formula. ( 27617986 )
2016
50
Lateral Chronic Cranial Window Preparation Enables In Vivo Observation Following Distal Middle Cerebral Artery Occlusion in Mice. ( 28060307 )
2016

Variations for Cerebral Artery Occlusion

Expression for Cerebral Artery Occlusion

Search GEO for disease gene expression data for Cerebral Artery Occlusion.

Pathways for Cerebral Artery Occlusion

Pathways related to Cerebral Artery Occlusion according to GeneCards Suite gene sharing:

(show all 12)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.18 BDNF CNTF GDNF IL16 NOS1 NOS3
2 11.58 BDNF GDNF NOS1
3
Show member pathways
11.28 NOS1 NOS3
4
Show member pathways
11.12 NOS1 NOS3
5
Show member pathways
11.08 NOS1 NOS3
6 11.03 BDNF CNTF GDNF
7
Show member pathways
10.96 NOS1 NOS3
8 10.88 NOS1 NOS3
9 10.78 NOS1 NOS3
10
Show member pathways
10.56 NOS1 NOS3 ODC1
11 10.37 NOS1 NOS3
12 10.06 NOS1 NOS3

GO Terms for Cerebral Artery Occlusion

Cellular components related to Cerebral Artery Occlusion according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.1 ADAMTS1 BDNF CNTF GDNF IL16 IL1RN
2 caveola GO:0005901 8.96 NOS1 NOS3

Biological processes related to Cerebral Artery Occlusion according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of neuron apoptotic process GO:0043524 9.61 BDNF CNTF GDNF
2 response to heat GO:0009408 9.52 NOS1 NOS3
3 negative regulation of blood pressure GO:0045776 9.51 NOS1 NOS3
4 vasodilation GO:0042311 9.49 NOS1 NOS3
5 regulation of sodium ion transport GO:0002028 9.48 NOS1 NOS3
6 nitric oxide mediated signal transduction GO:0007263 9.46 NOS1 NOS3
7 nitric oxide biosynthetic process GO:0006809 9.4 NOS1 NOS3
8 negative regulation of calcium ion transport GO:0051926 9.37 NOS1 NOS3
9 positive regulation of guanylate cyclase activity GO:0031284 9.32 NOS1 NOS3
10 negative regulation of potassium ion transport GO:0043267 9.26 NOS1 NOS3
11 ovulation from ovarian follicle GO:0001542 9.16 ADAMTS1 NOS3
12 arginine catabolic process GO:0006527 8.96 NOS1 NOS3
13 negative regulation of hydrolase activity GO:0051346 8.62 NOS1 NOS3

Molecular functions related to Cerebral Artery Occlusion according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.61 CNTF IL16 IL1RN
2 growth factor activity GO:0008083 9.58 BDNF CNTF GDNF
3 flavin adenine dinucleotide binding GO:0050660 9.49 NOS1 NOS3
4 scaffold protein binding GO:0097110 9.48 NOS1 NOS3
5 NADP binding GO:0050661 9.46 NOS1 NOS3
6 FMN binding GO:0010181 9.37 NOS1 NOS3
7 arginine binding GO:0034618 9.32 NOS1 NOS3
8 cadmium ion binding GO:0046870 9.26 NOS1 NOS3
9 NADPH-hemoprotein reductase activity GO:0003958 9.16 NOS1 NOS3
10 tetrahydrobiopterin binding GO:0034617 8.96 NOS1 NOS3
11 nitric-oxide synthase activity GO:0004517 8.62 NOS1 NOS3

Sources for Cerebral Artery Occlusion

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....